Skip to Content

First-line treatment of claudin 18.2-positive metastatic pancreatic cancer with zolbetuximab, gemcitabine, and nab-paclitaxel

Dr. Wungki Park presents an intriguing study of zolbetuximab in this MEDtalk. This innovative monoclonal antibody, which is the first of its kind, targets CLDN 18.2 and induces ADCC/CDC in patients with metastatic pancreatic cancer.

Wungki Park

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top